SUMMARY
This is AI generated summarization, which may have errors. For context, always refer to the full article.
Healthcare campaigners welcomed India’s rejection of a legal bid by Swiss company Novartis to patent a new version of its cancer drug, Glivec. The decision means generic drugmakers can continue to sell cheaper copies of Glivec in India, one of the fastest growing pharmaceutical markets. Indian authorities denied the firm’s plea on the grounds that the updated version was only slightly different from the previous one. Novartis said the Supreme Court’s ruling “discourages future innovation”.
Read more on BBC
Add a comment
How does this make you feel?
Loading
There are no comments yet. Add your comment to start the conversation.